Change of previously communicated allocation of the Group's interest-bearing liabilities
Recipharm AB published its interim report for January–March 2020 on May 7, 2020.
In the section Condensed consolidated statement of financial position the interim report stated that the item Non-current interest-bearing liabilities amounted to SEK 13,475.3 million and the item Current interest-bearing liabilities amounted to SEK 87.3 million. The correct allocation shall be that the item Non-current interest-bearing liabilities amounts to SEK 11,475.3 million and the item Current interest-bearing liabilities amounts to SEK 2,087.3 million.
The change does not affect the communicated key figures.
For more information please visit www.recipharm.com or contact:
Tobias Hägglöv, CFO, email@example.com, telephone: +46 8 602 52 00
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com